➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Dow
Express Scripts
Harvard Business School
Baxter

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Patent: 7,569,554

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,569,554
Title:Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents
Abstract: The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.
Inventor(s): Kandimalla; Ekambar R. (Southboro, MA), Agrawal; Sudhir (Shrewsbury, MA), Wang; Daqing (Bedford, MA), Bhagat; Lakshmi (Framingham, MA), Yu; Dong (Westboro, MA)
Assignee: Idera Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:10/846,167
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,569,554
Patent Claims:see list of patent claims

Details for Patent 7,569,554

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Idera Pharmaceuticals, Inc. (Cambridge, MA) 2023-05-16 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Idera Pharmaceuticals, Inc. (Cambridge, MA) 2023-05-16 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Idera Pharmaceuticals, Inc. (Cambridge, MA) 2023-05-16 RX Orphan search
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin VIAL;SINGLE-DOSE 761060 001 2018-04-09   Start Trial Idera Pharmaceuticals, Inc. (Cambridge, MA) 2023-05-16 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Idera Pharmaceuticals, Inc. (Cambridge, MA) 2023-05-16 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Boehringer Ingelheim
Mallinckrodt
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.